SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health safety and infectious disease markets in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | $93.78M |
| Gross Profit (TTM) | $40.85M |
| EBITDA | $21.21M |
| Operating Margin | -85.20% |
| Return on Equity | 11.00% |
| Return on Assets | 5.53% |
| Revenue/Share (TTM) | $1.31 |
| Book Value | $2.78 |
| Price-to-Book | 2.21 |
| Price-to-Sales (TTM) | 3.58 |
| EV/Revenue | 2.033 |
| EV/EBITDA | 8.99 |
| Quarterly Earnings Growth (YoY) | 1802.00% |
| Quarterly Revenue Growth (YoY) | -11.30% |
| Shares Outstanding | $71.72M |
| Float | $41.12M |
| % Insiders | 42.66% |
| % Institutions | 49.97% |
Volatility is currently expanding